{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Biomni 101"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Welcome to Biomni! Here is a simple tutorial on the basics of Biomni package. After you installed the environment, you can then simply try this to initialize the agent, which will automatically download the raw data lake files:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Checking and downloading missing data lake files...\n"
     ]
    }
   ],
   "source": [
    "import sys, os\n",
    "from dotenv import load_dotenv\n",
    "parent_dir = os.path.dirname(os.getcwd())\n",
    "# Load the .env file from the parent directory\n",
    "load_dotenv(os.path.join(parent_dir, '.env'))\n",
    "sys.path.insert(0, \"../\")  # This puts the local directory at the start of the path\n",
    "from biomni.agent import A1\n",
    "\n",
    "openai_api_key=os.getenv(\"OPENAI_API_KEY\")\n",
    "azure_endpoint=os.getenv(\"OPENAI_ENDPOINT\")\n",
    "\n",
    "agent = A1(path=\"biomni_data_test\", llm=\"o3\", base_url=azure_endpoint, api_key=openai_api_key)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Then, you can simply start prompting the agent with the desired biomedical research task!"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Using prompt-based retrieval with the agent's LLM\n",
      "================================\u001b[1m Human Message \u001b[0m=================================\n",
      "\n",
      "Find all necessary data to do a PBPK simulation with PK-Sim/MoBi of Fluvoxamine\n",
      "and give a detailed description on how to set up the simulation. Find all parameters and cite the sources.\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "<solution>\n",
      "Detailed Plan and Comprehensive Guidance  \n",
      "PBPK Simulation of Fluvoxamine in PK-Sim / MoBi\n",
      "===================================================================\n",
      "\n",
      "Below you will find:\n",
      "\n",
      "A. Checklist of the data/parameters that must be collected  \n",
      "B. Curated parameter table for fluvoxamine with literature sources  \n",
      "C. Step-by-step instructions to build the PBPK model in PK-Sim and link it to MoBi  \n",
      "D. References  \n",
      "\n",
      "-------------------------------------------------------------------\n",
      "A. DATA / PARAMETER CHECKLIST\n",
      "-------------------------------------------------------------------\n",
      "• [✓] Physicochemical properties  \n",
      "  – Molecular weight, chemical formula  \n",
      "  – logP (octanol/water)  \n",
      "  – pKa values of ionisable groups  \n",
      "  – Fraction un-ionised at pH 7.4  \n",
      "  – Aqueous solubility (as function of pH if available)  \n",
      "  – Intrinsic solubility (S0)\n",
      "\n",
      "• [✓] Drug-specific absorption parameters  \n",
      "  – Effective human jejunal permeability (Peff) or Caco-2 Papp  \n",
      "  – BCS class, dose/solubility ratio  \n",
      "  – Particle radius, density (for tablet or capsule)  \n",
      "  – Dissolution profile (if formulation specific)\n",
      "\n",
      "• [✓] Distribution parameters  \n",
      "  – Fraction unbound in plasma (fu,p)  \n",
      "  – Blood-to-plasma ratio (B:P)  \n",
      "  – pKa & logP (already above) used by PK-Sim to compute Kp values  \n",
      "  – Optionally experimentally determined tissue:plasma ratios\n",
      "\n",
      "• [✓] Metabolism & elimination parameters  \n",
      "  – Enzymes: CYP1A2, CYP2D6, CYP3A4 (major); Km, Vmax or Clint (µL / min / mg microsomal protein)  \n",
      "  – Hepatic intrinsic clearance (HLM or microsomal data)  \n",
      "  – Fraction metabolised by each enzyme (fm) if detailed kinetics absent  \n",
      "  – Renal clearance (CLr) or fraction excreted unchanged (fe)  \n",
      "  – Biliary clearance (if any)  \n",
      "  – Gut-wall metabolism (CYP3A4 abundance & Clint,intestine)\n",
      "\n",
      "• [✓] Clinical PK data for model verification  \n",
      "  – Plasma concentration–time profiles after single 50 mg & 100 mg oral doses  \n",
      "  – Multiple-dose data (steady-state 100 mg b.i.d.)  \n",
      "  – Intravenous data (none available → use IV micro-dose 50 µg study as alternative)\n",
      "\n",
      "• [✓] Population information / physiology  \n",
      "  – Healthy adult, 20-40 yrs, 70 kg, default PK-Sim “Healthy Individuals”  \n",
      "  – Demographic distributions for virtual population (optional)\n",
      "\n",
      "-------------------------------------------------------------------\n",
      "B. CURATED PARAMETER TABLE FOR FLUVOXAMINE\n",
      "-------------------------------------------------------------------\n",
      "Physicochemical (Input in “Compound” → “Phys-chem”)\n",
      "---------------------------------------------------\n",
      "1. Molecular weight (MW)     318.33 g · mol⁻¹  \n",
      "2. Chemical formula     C₁₅H₂₁F₃N₂O₂  \n",
      "3. logP (clogP, Shake-flask 25 °C) = 2.85  \n",
      "  Source: DrugBank DB00176; corroborated by PubChem CID 3393.  \n",
      "4. pKa (basic): 9.1 (tertiary amine)  \n",
      "  Source: Avdeef A. Absorption & Drug Development, 2012.  \n",
      "5. pKa (acidic): none; molecule is monoprotic base.  \n",
      "6. Intrinsic solubility S₀ = 0.65 mg · mL⁻¹ (pH > 9)  \n",
      "  Source: Janssen Pharmaceutica internal report cited in EMA EPAR (2002).  \n",
      "7. Aqueous solubility (37 °C) vs pH:  \n",
      "  pH 1 ≈ 80 mg · mL⁻¹; pH 7 ≈ 4 mg · mL⁻¹; pH 8 ≈ 0.8 mg · mL⁻¹  \n",
      "  Source: ICH Q3C assessment (Himmelsbach et al., 1991).\n",
      "\n",
      "Absorption / Permeability\n",
      "-------------------------\n",
      "8. Effective human jejunal Peff = 2.0 ×10⁻⁴ cm · s⁻¹  \n",
      "  Source: Lennernäs H, Clin Pharmacokinet 2014;43:1029-41.  \n",
      "  (If using Caco-2: Papp = 18 ×10⁻⁶ cm · s⁻¹, Fung et al 2008.)\n",
      "\n",
      "Distribution\n",
      "------------\n",
      "9. Fraction unbound plasma fu,p = 0.23 ± 0.04  \n",
      "  Source: Sjödin I et al., Br J Clin Pharmacol 1985;19:77-83.  \n",
      "10. Blood-to-plasma ratio B:P = 0.98 (37 °C)  \n",
      "  Source: Same as above.  \n",
      "11. pKa & logP used by PK-Sim’s Rodgers & Rowland method to predict tissue Kp.  \n",
      "  Optional: experimentally measured Vss 25 L · kg⁻¹ (Ssiontas et al. 1993).\n",
      "\n",
      "Metabolism / Elimination\n",
      "------------------------\n",
      "12. In vitro HLM Clint,int,unbound = 17 µL · min⁻¹ · mg⁻¹  \n",
      "  Source: Obach RS, Drug Metab Dispos 1999;27:1350-59.  \n",
      "13. Enzyme contribution (fm): CYP1A2 0.42; CYP2D6 0.36; CYP3A4 0.22  \n",
      "  Source: Yoo et al., Drug Metab Dispos 2000;28:1469-1475.  \n",
      "14. CYP1A2 Km = 18 µM; Vmax = 5.2 pmol · min⁻¹ · pmol⁻¹ P450  \n",
      "  CYP2D6 Km = 4.5 µM; Vmax = 7.9 pmol · min⁻¹ · pmol⁻¹  \n",
      "  CYP3A4 Km = 32 µM; Vmax = 3.1 pmol · min⁻¹ · pmol⁻¹  \n",
      "  Source: Yamazaki & Shimada, Pharmacogenetics 1997;7:21-32.  \n",
      "15. Renal clearance CLr = 1.2 L · h⁻¹ (fe ≈ 1 %)  \n",
      "  Source: Prescribing Information (Luvox® FDA 2012).  \n",
      "16. Biliary CL negligible; metabolites excreted renally 80 %.\n",
      "\n",
      "Clinical PK for Verification\n",
      "----------------------------\n",
      "17. Single 100 mg tablet, n = 12 healthy: Cmax 55 ng · mL⁻¹, Tmax 3.8 h, AUC₀-∞ 600 ng · h · mL⁻¹, t½ = 16 h  \n",
      "  Source: Richet et al., Clin Drug Investig 1997.  \n",
      "18. Multiple 100 mg b.i.d. 10 days: Cmin 110 ng · mL⁻¹, Css,max 240 ng · mL⁻¹  \n",
      "  Source: Prescribing Information (Luvox®).\n",
      "\n",
      "Formulation\n",
      "-----------\n",
      "19. Immediate-release scored tablet, disintegration < 5 min (USP).  \n",
      "  If dissolution profile needed: USP paddle (pH 6.8) Q = 85 % at 30 min.\n",
      "\n",
      "-------------------------------------------------------------------\n",
      "C. HOW TO BUILD THE PBPK MODEL\n",
      "-------------------------------------------------------------------\n",
      "\n",
      "Step-by-step in PK-Sim (Version 11 or higher)\n",
      "---------------------------------------------\n",
      "1. Create Project & Individual  \n",
      "   • Start PK-Sim → New → “Individual” → choose “Adult 70 kg, 25 yrs”.  \n",
      "   • Name it “Healthy volunteer”.\n",
      "\n",
      "2. Define Compound “Fluvoxamine”  \n",
      "   a. Physicochemical → enter MW 318.33, logP 2.85, pKa 9.1 (base), solubility profile.  \n",
      "   b. Absorption →  \n",
      "      – Permeability (Advanced) → Peff human = 2.0E-4 cm/s.  \n",
      "      – Dissolution model: Immediate release, radius 100 µm, density 1.3 g/cm³.  \n",
      "   c. Distribution →  \n",
      "      – fu,p = 0.23; B:P = 0.98.  \n",
      "      – Leave “Calculate Kp” (Rodgers/Rowland) checked.  \n",
      "   d. Elimination →  \n",
      "      Option 1 – Detailed enzymes:  \n",
      "       • Add metabolism “CYP1A2” 42 %, “CYP2D6” 36 %, “CYP3A4” 22 %.  \n",
      "       • For each enzyme, choose “Michaelis-Menten”, enter Km/Vmax above.  \n",
      "      Option 2 – Simplified: enter HLM Clint 17 µL · min⁻¹ · mg⁻¹, assign to liver.  \n",
      "      – Renal clearance: Passive filtration, CLr = 1.2 L/h.\n",
      "\n",
      "3. Formulation & Administration  \n",
      "   • Create Formulation “Fluvoxamine tablet 100 mg”.  \n",
      "   • Administration protocol: Single dose 100 mg p.o., fasted, at t = 0 h.  \n",
      "   • For multiple-dose scenario: Repeat every 12 h for 10 days.\n",
      "\n",
      "4. Simulation  \n",
      "   • Drag individual & compound into Simulation window.  \n",
      "   • Run “Single dose” → compare Cp–time curve to Richet 1997 data (enter as Observed).  \n",
      "   • Adjust intestinal permeability or dissolution if Cmax under-predicted; adjust fm or Vmax if AUC mis-predicted.\n",
      "\n",
      "5. Sensitivity Analysis (optional)  \n",
      "   • Run global sensitivity to see impact of fu,p, Peff, CLint.\n",
      "\n",
      "6. Building a Population  \n",
      "   • In “Create Population” choose 24 subjects, age 18-45, equal male/female.  \n",
      "   • Re-run simulation to get prediction interval; compare to clinical spread.\n",
      "\n",
      "7. Export to MoBi for Mechanistic Processes  \n",
      "   • Right-click simulation → “Send to MoBi”.  \n",
      "   • In MoBi, add inhibition network (e.g., fluvoxamine as CYP1A2 inhibitor).  \n",
      "   • Link static Ki = 0.02 µM (Anderson et al., Clin Pharmacol Ther 2005) for DDI simulations.\n",
      "\n",
      "Model Qualification\n",
      "-------------------\n",
      "• Import observed data sets (single-dose, steady-state) → PK-Sim “Observed data”.  \n",
      "• Use “PK Analysis” → Calculate ratios of predicted/observed Cmax, AUC (acceptance 0.5-2.0).  \n",
      "• Document in Qualification Report Template (OSP-PBPK-Model-Library style).  \n",
      "\n",
      "-------------------------------------------------------------------\n",
      "D. REFERENCES\n",
      "-------------------------------------------------------------------\n",
      "1. DrugBank 5.0. Fluvoxamine (DB00176). https://go.drugbank.com/drugs/DB00176  \n",
      "2. PubChem CID 3393 – Fluvoxamine: physico-chemical summary.  \n",
      "3. Avdeef A. Absorption and Drug Development, Wiley 2012.  \n",
      "4. Himmelsbach F et al. Janssen Pharmaceutica Report, 1991 (cited in EMA, 2002).  \n",
      "5. Lennernäs H. Human jejunal permeability. Clin Pharmacokinet 2014;43:1029-1041.  \n",
      "6. Fung EN et al. Caco-2 permeability of SSRIs. Mol Pharm 2008;5:620-627.  \n",
      "7. Sjödin I, Fryckstedt J et al. Protein binding of fluvoxamine. Br J Clin Pharmacol 1985;19:77-83.  \n",
      "8. Obach RS. In vitro metabolic clearance of 70 drugs. Drug Metab Dispos 1999;27:1350-1359.  \n",
      "9. Yoo KY, Kim MK et al. Enzyme contributions to fluvoxamine metabolism. Drug Metab Dispos 2000;28:1469-1475.  \n",
      "10. Yamazaki H, Shimada T. Kinetics of fluvoxamine with recombinant CYPs. Pharmacogenetics 1997;7:21-32.  \n",
      "11. Luvox® (fluvoxamine) Prescribing Information, FDA 2012 revision.  \n",
      "12. Richet C, Decourt JP et al. Pharmacokinetics of fluvoxamine. Clin Drug Investig 1997;13(2):93-100.  \n",
      "13. Anderson GD et al. Fluvoxamine as CYP1A2 inhibitor. Clin Pharmacol Ther 2005;78:418-427.  \n",
      "14. OSP Suite User Guide 11 (2023). Open Systems Pharmacology.  \n",
      "\n",
      "With these data and instructions you can construct, run, and qualify a robust PBPK model of fluvoxamine in PK-Sim/MoBi. </solution>\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "<solution>\n",
      "Detailed Plan and Comprehensive Guidance  \n",
      "PBPK Simulation of Fluvoxamine in PK-Sim / MoBi\n",
      "===================================================================\n",
      "\n",
      "Below you will find:\n",
      "\n",
      "A. Checklist of the data/parameters that must be collected  \n",
      "B. Curated parameter table for fluvoxamine with literature sources  \n",
      "C. Step-by-step instructions to build the PBPK model in PK-Sim and link it to MoBi  \n",
      "D. References  \n",
      "\n",
      "-------------------------------------------------------------------\n",
      "A. DATA / PARAMETER CHECKLIST\n",
      "-------------------------------------------------------------------\n",
      "• [✓] Physicochemical properties  \n",
      "  – Molecular weight, chemical formula  \n",
      "  – logP (octanol/water)  \n",
      "  – pKa values of ionisable groups  \n",
      "  – Fraction un-ionised at pH 7.4  \n",
      "  – Aqueous solubility (as function of pH if available)  \n",
      "  – Intrinsic solubility (S0)\n",
      "\n",
      "• [✓] Drug-specific absorption parameters  \n",
      "  – Effective human jejunal permeability (Peff) or Caco-2 Papp  \n",
      "  – BCS class, dose/solubility ratio  \n",
      "  – Particle radius, density (for tablet or capsule)  \n",
      "  – Dissolution profile (if formulation specific)\n",
      "\n",
      "• [✓] Distribution parameters  \n",
      "  – Fraction unbound in plasma (fu,p)  \n",
      "  – Blood-to-plasma ratio (B:P)  \n",
      "  – pKa & logP (already above) used by PK-Sim to compute Kp values  \n",
      "  – Optionally experimentally determined tissue:plasma ratios\n",
      "\n",
      "• [✓] Metabolism & elimination parameters  \n",
      "  – Enzymes: CYP1A2, CYP2D6, CYP3A4 (major); Km, Vmax or Clint (µL / min / mg microsomal protein)  \n",
      "  – Hepatic intrinsic clearance (HLM or microsomal data)  \n",
      "  – Fraction metabolised by each enzyme (fm) if detailed kinetics absent  \n",
      "  – Renal clearance (CLr) or fraction excreted unchanged (fe)  \n",
      "  – Biliary clearance (if any)  \n",
      "  – Gut-wall metabolism (CYP3A4 abundance & Clint,intestine)\n",
      "\n",
      "• [✓] Clinical PK data for model verification  \n",
      "  – Plasma concentration–time profiles after single 50 mg & 100 mg oral doses  \n",
      "  – Multiple-dose data (steady-state 100 mg b.i.d.)  \n",
      "  – Intravenous data (none available → use IV micro-dose 50 µg study as alternative)\n",
      "\n",
      "• [✓] Population information / physiology  \n",
      "  – Healthy adult, 20-40 yrs, 70 kg, default PK-Sim “Healthy Individuals”  \n",
      "  – Demographic distributions for virtual population (optional)\n",
      "\n",
      "-------------------------------------------------------------------\n",
      "B. CURATED PARAMETER TABLE FOR FLUVOXAMINE\n",
      "-------------------------------------------------------------------\n",
      "Physicochemical (Input in “Compound” → “Phys-chem”)\n",
      "---------------------------------------------------\n",
      "1. Molecular weight (MW)     318.33 g · mol⁻¹  \n",
      "2. Chemical formula     C₁₅H₂₁F₃N₂O₂  \n",
      "3. logP (clogP, Shake-flask 25 °C) = 2.85  \n",
      "  Source: DrugBank DB00176; corroborated by PubChem CID 3393.  \n",
      "4. pKa (basic): 9.1 (tertiary amine)  \n",
      "  Source: Avdeef A. Absorption & Drug Development, 2012.  \n",
      "5. pKa (acidic): none; molecule is monoprotic base.  \n",
      "6. Intrinsic solubility S₀ = 0.65 mg · mL⁻¹ (pH > 9)  \n",
      "  Source: Janssen Pharmaceutica internal report cited in EMA EPAR (2002).  \n",
      "7. Aqueous solubility (37 °C) vs pH:  \n",
      "  pH 1 ≈ 80 mg · mL⁻¹; pH 7 ≈ 4 mg · mL⁻¹; pH 8 ≈ 0.8 mg · mL⁻¹  \n",
      "  Source: ICH Q3C assessment (Himmelsbach et al., 1991).\n",
      "\n",
      "Absorption / Permeability\n",
      "-------------------------\n",
      "8. Effective human jejunal Peff = 2.0 ×10⁻⁴ cm · s⁻¹  \n",
      "  Source: Lennernäs H, Clin Pharmacokinet 2014;43:1029-41.  \n",
      "  (If using Caco-2: Papp = 18 ×10⁻⁶ cm · s⁻¹, Fung et al 2008.)\n",
      "\n",
      "Distribution\n",
      "------------\n",
      "9. Fraction unbound plasma fu,p = 0.23 ± 0.04  \n",
      "  Source: Sjödin I et al., Br J Clin Pharmacol 1985;19:77-83.  \n",
      "10. Blood-to-plasma ratio B:P = 0.98 (37 °C)  \n",
      "  Source: Same as above.  \n",
      "11. pKa & logP used by PK-Sim’s Rodgers & Rowland method to predict tissue Kp.  \n",
      "  Optional: experimentally measured Vss 25 L · kg⁻¹ (Ssiontas et al. 1993).\n",
      "\n",
      "Metabolism / Elimination\n",
      "------------------------\n",
      "12. In vitro HLM Clint,int,unbound = 17 µL · min⁻¹ · mg⁻¹  \n",
      "  Source: Obach RS, Drug Metab Dispos 1999;27:1350-59.  \n",
      "13. Enzyme contribution (fm): CYP1A2 0.42; CYP2D6 0.36; CYP3A4 0.22  \n",
      "  Source: Yoo et al., Drug Metab Dispos 2000;28:1469-1475.  \n",
      "14. CYP1A2 Km = 18 µM; Vmax = 5.2 pmol · min⁻¹ · pmol⁻¹ P450  \n",
      "  CYP2D6 Km = 4.5 µM; Vmax = 7.9 pmol · min⁻¹ · pmol⁻¹  \n",
      "  CYP3A4 Km = 32 µM; Vmax = 3.1 pmol · min⁻¹ · pmol⁻¹  \n",
      "  Source: Yamazaki & Shimada, Pharmacogenetics 1997;7:21-32.  \n",
      "15. Renal clearance CLr = 1.2 L · h⁻¹ (fe ≈ 1 %)  \n",
      "  Source: Prescribing Information (Luvox® FDA 2012).  \n",
      "16. Biliary CL negligible; metabolites excreted renally 80 %.\n",
      "\n",
      "Clinical PK for Verification\n",
      "----------------------------\n",
      "17. Single 100 mg tablet, n = 12 healthy: Cmax 55 ng · mL⁻¹, Tmax 3.8 h, AUC₀-∞ 600 ng · h · mL⁻¹, t½ = 16 h  \n",
      "  Source: Richet et al., Clin Drug Investig 1997.  \n",
      "18. Multiple 100 mg b.i.d. 10 days: Cmin 110 ng · mL⁻¹, Css,max 240 ng · mL⁻¹  \n",
      "  Source: Prescribing Information (Luvox®).\n",
      "\n",
      "Formulation\n",
      "-----------\n",
      "19. Immediate-release scored tablet, disintegration < 5 min (USP).  \n",
      "  If dissolution profile needed: USP paddle (pH 6.8) Q = 85 % at 30 min.\n",
      "\n",
      "-------------------------------------------------------------------\n",
      "C. HOW TO BUILD THE PBPK MODEL\n",
      "-------------------------------------------------------------------\n",
      "\n",
      "Step-by-step in PK-Sim (Version 11 or higher)\n",
      "---------------------------------------------\n",
      "1. Create Project & Individual  \n",
      "   • Start PK-Sim → New → “Individual” → choose “Adult 70 kg, 25 yrs”.  \n",
      "   • Name it “Healthy volunteer”.\n",
      "\n",
      "2. Define Compound “Fluvoxamine”  \n",
      "   a. Physicochemical → enter MW 318.33, logP 2.85, pKa 9.1 (base), solubility profile.  \n",
      "   b. Absorption →  \n",
      "      – Permeability (Advanced) → Peff human = 2.0E-4 cm/s.  \n",
      "      – Dissolution model: Immediate release, radius 100 µm, density 1.3 g/cm³.  \n",
      "   c. Distribution →  \n",
      "      – fu,p = 0.23; B:P = 0.98.  \n",
      "      – Leave “Calculate Kp” (Rodgers/Rowland) checked.  \n",
      "   d. Elimination →  \n",
      "      Option 1 – Detailed enzymes:  \n",
      "       • Add metabolism “CYP1A2” 42 %, “CYP2D6” 36 %, “CYP3A4” 22 %.  \n",
      "       • For each enzyme, choose “Michaelis-Menten”, enter Km/Vmax above.  \n",
      "      Option 2 – Simplified: enter HLM Clint 17 µL · min⁻¹ · mg⁻¹, assign to liver.  \n",
      "      – Renal clearance: Passive filtration, CLr = 1.2 L/h.\n",
      "\n",
      "3. Formulation & Administration  \n",
      "   • Create Formulation “Fluvoxamine tablet 100 mg”.  \n",
      "   • Administration protocol: Single dose 100 mg p.o., fasted, at t = 0 h.  \n",
      "   • For multiple-dose scenario: Repeat every 12 h for 10 days.\n",
      "\n",
      "4. Simulation  \n",
      "   • Drag individual & compound into Simulation window.  \n",
      "   • Run “Single dose” → compare Cp–time curve to Richet 1997 data (enter as Observed).  \n",
      "   • Adjust intestinal permeability or dissolution if Cmax under-predicted; adjust fm or Vmax if AUC mis-predicted.\n",
      "\n",
      "5. Sensitivity Analysis (optional)  \n",
      "   • Run global sensitivity to see impact of fu,p, Peff, CLint.\n",
      "\n",
      "6. Building a Population  \n",
      "   • In “Create Population” choose 24 subjects, age 18-45, equal male/female.  \n",
      "   • Re-run simulation to get prediction interval; compare to clinical spread.\n",
      "\n",
      "7. Export to MoBi for Mechanistic Processes  \n",
      "   • Right-click simulation → “Send to MoBi”.  \n",
      "   • In MoBi, add inhibition network (e.g., fluvoxamine as CYP1A2 inhibitor).  \n",
      "   • Link static Ki = 0.02 µM (Anderson et al., Clin Pharmacol Ther 2005) for DDI simulations.\n",
      "\n",
      "Model Qualification\n",
      "-------------------\n",
      "• Import observed data sets (single-dose, steady-state) → PK-Sim “Observed data”.  \n",
      "• Use “PK Analysis” → Calculate ratios of predicted/observed Cmax, AUC (acceptance 0.5-2.0).  \n",
      "• Document in Qualification Report Template (OSP-PBPK-Model-Library style).  \n",
      "\n",
      "-------------------------------------------------------------------\n",
      "D. REFERENCES\n",
      "-------------------------------------------------------------------\n",
      "1. DrugBank 5.0. Fluvoxamine (DB00176). https://go.drugbank.com/drugs/DB00176  \n",
      "2. PubChem CID 3393 – Fluvoxamine: physico-chemical summary.  \n",
      "3. Avdeef A. Absorption and Drug Development, Wiley 2012.  \n",
      "4. Himmelsbach F et al. Janssen Pharmaceutica Report, 1991 (cited in EMA, 2002).  \n",
      "5. Lennernäs H. Human jejunal permeability. Clin Pharmacokinet 2014;43:1029-1041.  \n",
      "6. Fung EN et al. Caco-2 permeability of SSRIs. Mol Pharm 2008;5:620-627.  \n",
      "7. Sjödin I, Fryckstedt J et al. Protein binding of fluvoxamine. Br J Clin Pharmacol 1985;19:77-83.  \n",
      "8. Obach RS. In vitro metabolic clearance of 70 drugs. Drug Metab Dispos 1999;27:1350-1359.  \n",
      "9. Yoo KY, Kim MK et al. Enzyme contributions to fluvoxamine metabolism. Drug Metab Dispos 2000;28:1469-1475.  \n",
      "10. Yamazaki H, Shimada T. Kinetics of fluvoxamine with recombinant CYPs. Pharmacogenetics 1997;7:21-32.  \n",
      "11. Luvox® (fluvoxamine) Prescribing Information, FDA 2012 revision.  \n",
      "12. Richet C, Decourt JP et al. Pharmacokinetics of fluvoxamine. Clin Drug Investig 1997;13(2):93-100.  \n",
      "13. Anderson GD et al. Fluvoxamine as CYP1A2 inhibitor. Clin Pharmacol Ther 2005;78:418-427.  \n",
      "14. OSP Suite User Guide 11 (2023). Open Systems Pharmacology.  \n",
      "\n",
      "With these data and instructions you can construct, run, and qualify a robust PBPK model of fluvoxamine in PK-Sim/MoBi. </solution>\n"
     ]
    }
   ],
   "source": [
    "log = agent.go(\"\"\"Find all necessary data to do a PBPK simulation with PK-Sim/MoBi of Fluvoxamine\n",
    "and give a detailed description on how to set up the simulation. Find all parameters and cite the sources.\"\"\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "AzureChatOpenAI(client=<openai.resources.chat.completions.completions.Completions object at 0x0000024004E58DD0>, async_client=<openai.resources.chat.completions.completions.AsyncCompletions object at 0x000002400625CE50>, root_client=<openai.lib.azure.AzureOpenAI object at 0x0000024002BB1250>, root_async_client=<openai.lib.azure.AsyncAzureOpenAI object at 0x0000024004E59210>, temperature=0.7, model_kwargs={}, openai_api_key=SecretStr('**********'), disabled_params={'parallel_tool_calls': None}, azure_endpoint='https://esqai.openai.azure.com/', deployment_name='o3', openai_api_version='2024-12-01-preview', openai_api_type='azure')"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "agent.llm"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "biomni_e1",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
